Journal List > Allergy Asthma Immunol Res > v.6(1) > 1052386

TOOLS
Losol, Yoo, and Park: Molecular Genetic Mechanisms of Chronic Urticaria
Review

Allergy, Asthma & Immunology Research 2014; 6(1): 13-21.

Published online: 30 October 2013

DOI: https://doi.org/10.4168/aair.2014.6.1.13

Molecular Genetic Mechanisms of Chronic Urticaria

Purevsuren Losol, Hye-Soo Yoo, Hae-Sim Park

Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea.

Correspondence to: Hae-Sim Park, MD, PhD, Professor, Department of Allergy and Clinical Immunology, Ajou University School of Medicine, 206 World cup-ro, Yeongtong-gu, Suwon 443-721, Korea. Tel: +82-31-219-5196; Fax: +82-31-219-5154; hspark@ajou.ac.kr

Received 4 March 2013       Accepted 15 April 2013

Copyright © 2014 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Chronic urticaria (CU) is a common allergic skin disease that requires long-term pharmacological treatment. Some patients with severe CU suffer a poor quality of life. Although the pathogenic mechanisms of CU are not clearly understood, several groups have suggested that genetic mechanisms are involved in various CU cohorts. To further understand the molecular genetic mechanisms of CU, we summarize recent genetic data in this review. Although a few HLA alleles were suggested to be candidate markers in different ethnic groups, further replication studies that apply the recent classification are needed. Genetic polymorphisms in histamine-related genes, including FcεRI and HNMT, were suggested to be involved in mast cell activation and histamine metabolism. Several genetic polymorphisms of leukotriene-related genes, such as ALOX5, LTC4S, and the PGE2 receptor gene PTGER4, were suggested to be involved in leukotriene overproduction, a pathogenic mechanism. Further investigations using candidate gene approaches and genome-wide association studies (GWAS) will provide new insights into the molecular genetic mechanisms of CU, which will provide new marker genes for differentiation of CU phenotypes and identification of potential therapeutic targets.

Keywords: Chronic urticaria, genetic association, leukotriene, mast cell

Urticaria is a common skin disorder, affecting 15%-30% of the population and leading to consultations at medical facilities. Chronic urticaria (CU) accounts for 25% of urticaria and the point prevalence of CU is 0.5%-1%.1,2 CU is characterized by the presence of hives, on most days of the week, for over 6 weeks. However, the classification of CU has been updated and the terminology has evolved and become more specific, as a result of increasing understanding of the causes of, and eliciting factors in, urticaria. Despite this increased understanding, appreciable numbers of CU patients are classified as idiopathic, implying an unknown origin.3 Furthermore, the underlying causes and pathophysiological mechanisms of CU are not fully understood. Allergic diseases are complex, and are regulated by the interaction between genetic and environmental factors. Over the last few years, genetic studies of allergic diseases have become more advanced, especially of asthma. Similar to asthma and other allergic diseases, genetic mechanisms may be associated with the pathogenesis of CU. A study in a large population of patients with CU showed an increased prevalence of the disorder among first-degree relatives compared to the general population.4 Several recent genetic studies aimed to determine the genetic predisposition to CU. Genetic factors doubtless make important contributions to susceptibility to disease development and progression, especially in particular CU subtypes; e.g., aspirin-intolerant CU.

CLINICAL CHARACTERISTICS OF CU

CU is defined when it occurs spontaneously, without demonstrable provocations, unlike physical and other inducible urticaria.5 About 40% of patients with CU experience concurrent angioedema.6 The majority of studies of CU show that females are affected nearly twice as often as males, and that the peak age of manifestation of CU is 20-40 years.1,7-9 Common provoking factors, such as physical factors, cold, heat, food, food additives, viral infection, psychological factors, endocrine diseases, and drugs, aggravate the symptoms.3,5,10-13 One of the most common drugs which elicit urticaria is aspirin and other nonsteroidal anti-inflammatory drugs (NSAID).14,15 Ingestion of aspirin or other NSAIDs, which inhibit cyclooxygenase, exacerbates the underlying conditions of CU and induces hives, namely aspirin-intolerant chronic urticaria (AICU), while patients who develop acute urticaria whenever they are exposed to aspirin/NSAIDs are called as having aspirin-intolerant acute urticaria (AIAU). One recent study proposed that AICU be described as aspirin-exacerbated cutaneous disease (AECD), similarly to aspirin-exacerbated respiratory disease (AERD),16 the prevalence of which may be as high as 27%-35% in patients with CU.17 AICU is confirmed by oral aspirin challenge test; no reliable in vitro test is available.18 Based on oral challenge tests, CU can be classified as AICU or aspirin-tolerant CU (ATCU).
Genetic epidemiology studies of AICU in a Korean population suggested that atopy and increased serum total IgE levels are major predisposing factors for the AICU phenotype.19,20 Patients with AICU were found to be younger and to have higher atopy rates, higher total serum IgE levels, and greater associations with a history of asthma compared to those with ATCU (Table 1). AICU had a longer duration of CU symptoms and presented with more severe symptoms requiring higher doses of drugs, including oral corticosteroids. However, no significant differences were noted in the prevalences of serum thyroid autoantibodies and antinuclear antibody (ANA) between AICU and ATCU.19 Few reports compared the clinical features and pathogenic mechanisms of AIAU and AICU. In those available at present, there were no significant differences in mean age, gender distribution, serum total IgE, or the prevalences of atopy, allergic rhinitis, asthma, or food allergy between the two groups.21,22 However, levels of a neutrophil activation marker were significantly higher in AIAU patients than in those with AICU.21 Atopy was also a major predisposing factor for the AIAU phenotype.22

THE CANDIDATE GENE APPROACH IN CU

The first target genes identified using the candidate gene approach were those related to mast cell activation and histamine including, FcεRI, HNMT, HRH1, HRH2, TNF-α, TGFβ1, ADORA3, and IL-10. Also identified were genes related to the arachidonic acid (AA) pathway, including ALOX5, CysLTR1, LTC4S, and PTGER4, and HLA class I and II alleles. Other genes that could be involved in CU pathogenesis were UGT1A6, CYP2C9, NAT2, ACE, and PTPN22 (Table 2).

Molecular genetic mechanisms related with mast cell activation and histamine

Mast cells are the major effector cell type that release histamine, cytokines and chemical mediators involved in the pathogenic mechanisms of CU. IgE binds with high affinity to a receptor (FcεRI) on the mast cell surface to induce activation, and CU patients show increased basophil histamine release.23 Anti-IgE therapy is considered as an effective treatment to control urticaria symptoms in CU patients.24 Moreover, CU is thought to have an autoimmune background because of the presence of circulating histamine-releasing IgG autoantibodies against FcεRI, which could induce degranulation of basophils and cutaneous mast cells.25,26 Various types of serum autoantibody, such as ANA and IgGs against thyroglobulin and thyroid peroxidase (TPO), were elevated in sera from CU patients, although it is unknown how these autoantibodies are involved in the pathogenic mechanism.3,7,27 One recent study demonstrated the presence of highly cytokinergic serum IgE antibodies specific for various autoantigens, such as TPO on the mast cell surface, which could activate mast cells.28 When mast cells are triggered, they release preformed mediators, and subsequently leukotrienes, prostaglandins, cytokines, and chemokines, which aggravate chronic inflammation.29,30 FcεRI is a tetramer consisting of a ligand-binding α chain, a signal-amplifying β chain, and a signal-transducing γ chain dimer.31,32 Recent studies have demonstrated their roles in aspects of molecular genetic mechianism of CU. When the genotype frequency of the FcεRIα gene was analyzed in CU patients comparing between AICU and ATCU patients, the minor allele FcεRIα -344C>T polymorphism showed a higher frequency in patients with AICU than in those with ATCU and normal controls in a Korean population.33 In vitro functional analysis showed that this allele induced significantly higher promoter activity. Moreover, basophils in AICU patients with this allele showed increased histamine-releasing capacity. These findings suggest that this functional polymorphism may modulate FcεRIα expression on mast cells, enhancing histamine release and increasing susceptibility to AICU. A further study of FcεRIβ indicated that two genetic polymorphisms, FcεRIβ E237G and FcεRIγ -237A>G, were associated with atopy rate in AICU patients, but not in ATCU patients, in a Korean population.34 The AG/GG genotype of the FcεRIβ E237G and FcεRIγ -237G alleles was associated with risk of atopy in AICU patients. Moreover, histamine release from basophils induced by anti-IgE antibodies was significantly higher in AICU patients with atopy than in those without atopy, suggesting that atopy may contribute to increased histamine release from basophils in AICU patients. These findings suggest that genetic variations in the FcεRI gene could modulate expression of this receptor on the mast cell surface, and so histamine release from mast cells/basophils in CU patients, especially those with atopy.
Histamine is formed by the histamine synthesis enzyme, L-histidine decarboxylase and its local action is terminated by histamine N-methyltransferase (HNMT) and diamine oxidase.35,36 We hypothesized that a genetic variant at HNMT (939A>G) is a risk factor for CU.37 When this polymorphism was assessed in CU patients including AICU and ATCU groups compared to NC group, the frequency of the major allele was significantly higher in AICU group compared to the control group in a Korean population. Moreover, in vitro functional analysis showed that the 939A allele was associated with decreased mRNA stability and enzyme activity, indicating that this genetic polymorphism at HNMT 939A>G modulates HNMT enzyme activity, thereby contributing to the development of CU. The diverse functions of histamine are mediated by G-protein-coupled H1 to H4 receptors. However, a genetic association study showed that histamine receptor H1 (HRH1) (-17C>T) and HRH2 (543G>A) polymorphisms were not significant risk factors for this type of urticaria.38
Tumor necrosis factor (TNF)-α is a proinflammatory cytokine that is synthesized, stored, and released by mast cells during allergic inflammation. TNF-α can be found at the site of urticarial lesions, and several studies have shown upregulation of TNF-α expression in CU patients.39,40 TNF-α genetic variants with high transcriptional activity may upregulate TNF-α production by mast cells and so contribute to the pathogenesis of CU. The TNF-α gene is located on chromosome 6 and may interact with the HLA class I and II alleles.41 Recently, it was demonstrated that TNF-α polymorphisms at -1031T>C and -863C>A, and their haplotype, were significantly associated with the aspirin-induced urticaria (AIU) phenotype compared to healthy controls in a Korean population.42 Moreover, Japanese investigators showed higher levels of TNF-α transcription for the -1031C, -863A, and -857T alleles, demonstrating that these three alleles were in significant linkage disequilibrium with HLA-B61, -B39, and -DRB1*0901, and with HLA-B54, -B35, -B59, and -DRB1*0405, respectively.43
The multipotent cytokine transforming growth factor (TGF)-β1 may be related to CU phenotypes due to its positive and negative effects on mast cell function. TGF-β1 is expressed by airway epithelial cells, eosinophils, Th2 lymphocytes, macrophages, and fibroblasts.44 Studies of the effects of TGFβ1 on mast cell effector functions showed that TGF-β1 inhibits FcεRI expression and degranulation of mast cells.45,46 Genetic effects of TGFβ1 in different allergic disorders, including CU, have been described. The major allele frequency at TGFβ1 -509C>T was significantly higher in CU patients in an Iranian population.47 In contrast, the minor allele frequency of -509C>T was significantly higher in AICU patients in a Korean population, and this allele tended to be associated with a lower serum level of TGF-β1.48,49 The minor allele of this variant, TGFβ1 -509T, was identified as a risk factor in patients with AERD and asthma in two studies.49,50 Patients carrying the minor allele had lower serum TGF-β1 levels and higher transcriptional activity. These findings suggest that TGFβ1 genetic variants could be involved in the modulation of mast cell function and may contribute to the development of CU.
Adenosine is an endogenous nucleoside that can be released from stimulated mast cells.51 It increases cutaneous vasopermeability and edema formation by activating A2B (ADORA2B) and A3 receptors (ADORA3) expressed on human mast cells, and facilitates the release of histamine, prostaglandins, leukotrienes, and proinflammatory cytokines.52,53 Two functional genetic variants of the adenosine A3 receptor (ADORA3) gene at -1050G>T and -564C>T have been identified as genetic risk factors for AIU, including AICU, in a Korean population; ADORA3 -1050G>T and haplotype 1 [TC; -1050T and -564C] showed significant associations in AIU patients.54 Moreover, this haplotype showed higher promoter activity and increased basophil histamine release, indicating that the ADORA3 gene polymorphism could enhance histamine release through increased ADORA3 expression in CU patients.
Interleukin (IL)-10 is an anti-inflammatory cytokine that is expressed in a wide range of cells of the adaptive and innate immune systems and that plays an essential role in the regulation of immune responses.55-57 Moreover, it has been shown to induce pro- and anti-inflammatory responses.55 The genetic variants -1082A/G, -819C/T, and 592A/C in the promoter region of the IL-10 gene have been described frequently in association with cutaneous diseases, while their influence on IL-10 production is unclear.58-61 A genetic association of -819T>C in IL-10 with AIU, including both AIAU and AICU, was identified in a Korean population.62 The authors demonstrated a significantly higher frequency of the major allele of IL-10 -819T>C in those with AIU phenotypes. Some evidence indicates that IL-10 can suppress FcεRI expression in human skin-derived mast cells.63 This effect was confirmed in mouse mast cells since IL-10 suppressed both signaling molecule and IgE-mediated cytokine production. A similar study demonstrated that mast cell-derived IL-10 could limit leukocyte infiltration, epidermal hyperplasia, and epidermal necrosis in a mouse model.64 This evidence indicates that downregulation of IL-10 production as a result of genetic predisposition may facilitate mast cell degranulation and aggravate CU.

Genes involved in the arachidonic acid pathway

Aberrant arachidonic acid (AA) metabolism, especially cyclooxygenase (COX) and arachidonate 5-lipoxygenase (5-LO or ALOX5) pathways, account for the susceptibility to CU phenotypes following the ingestion of aspirin or NSAIDs.65 The ALOX5 gene encodes the enzyme 5-LO, which acts with arachidonate 5-lipoxygenase-activating protein (ALOX5AP/FLAP) to catalyze the first two steps in synthesis of leukotriene A4 (LTA4).66 LTA4 is converted to a variety of leukotrienes, such as LTC4, LTD4, and LTE4, by leukotriene C4 synthase (LTC4S). Cysteinyl leukotrienes bind to and activate two receptors belonging to the G-protein-coupled receptors (GPCR) superfamily, CysLTR1 and CysLTR2, with different affinities. In contrast, prostaglandins and thromboxanes are synthesized via the COX pathway and show inhibitory effects on the release of CysLTs from activated mast cells.67 Prostaglandin E2 (PGE2) binds to a specific group of four GPCR subtypes, EP1- EP4, which are expressed on the mast cell surface and responsible for PGE2 activity.68
Recently, AA pathway-related genetic variants were studied in NSAID-induced acute urticaria patients among two different Spanish populations.69 Genetic variants in ALOX5AP (218A>G), ALOX15 (-272C>A), PTGDR (-549T>C), PTGER1 (-1013A>C and -804C>T), PTGER2 (-72G>A), and CysLTR1 (927C>T) showed significant associations with this clinical phenotype.
Most genetic studies of this pathway have focused on whether these genetic polymorphisms can be used to differentiate two major phenotypes of aspirin hypersensitivity, AERD and AIU. Genetic variants in ALOX5 (-1708G>A, 270G>A and 1728A>G) and ALOX5AP (218A>G) were identified in a Korean population, with ALOX5 -1708G>A, haplotype 1 [GGA; -1708G, 270G, and 1728A] and haplotype 2 [AGA; -1708A, 270G, 1728A] differing significantly between AIU and AERD phenotypes.70 Similarly, a significant association was noted for the CysLTR1 -634C>T variant and the AICU phenotype compared to AERD.71 Moreover, haplotype 2 [TCG: -634T, -475C, and -336G] showed higher promoter activity compared to other haplotypes haplotypes. These findings suggest that the contributions of ALOX5 and CysLTR1 genetic variants differ between AICU and AERD.
Leukotriene C4 synthase (LTC4S) is a terminal enzyme in the leukotriene pathway and is responsible for the production of CysLTs, the levels of which are characteristically increased after aspirin exposure in AICU patients.29,65,72 Genetic variability in the functional polymorphism in LTC4S, which increases the expression of this gene, has been reported in different ethnic groups. The LTC4S -444A>C genetic variant was significantly associated with AIU in a Venezuelan population, as well with the cutaneous clinical pattern and a low skin response to histamine.73 Elsewhere, in a Polish population, the variant allele of the LTC4S -444A>C polymorphism was inherited in families with AIU.74 Attempts to replicate this association in Spanish75 and Korean populations were unsuccessful.71
A genetic variant in the PGE2 receptor subtype EP4 (PTGER4) at -1254A>G was significantly associated with AICU in a Korean population.20 The minor allele of this polymorphism had a high frequency in AICU patients, and showed lower PTGER4 promoter activity with decreased expression of PTGER4 in human mast cells. That this functional variant modulates PTGER4 gene expression was confirmed by lower transcriptional regulation of PTGER4, suggesting that PTGER4 expression could lose its protective effect after aspirin exposure in subjects carrying this risk allele, which contributes to the development of AICU.

HLA class I and class II alleles

HLA class I and II alleles, which may affect MHC binding capacity, are well known genetic markers of CU phenotypes in various ethnic groups (Table 3). HLA class I alleles have been investigated less often than HLA class II alleles. A possible protective role for HLA-A24 (Turkey)76 and -A33 (Poland)77 was identified in CU. However, the HLA antigens HLA-Bw4 (Turkey),76 -B14 (Brazil),78 and -B44 (Poland and Turkey)77,79 may be responsible for susceptibility to CU. Notably, the prevalence of HLA-B14 was higher in patients with CU with high IgG to TPO levels.78 AICU and HLA class I antigen showed a strong correlation in an Italian population.80 HLA-B44 and -Cw5 allele frequencies are higher in AICU, while HLA-A11, -B13, -Cw4 and Cw7 allele frequencies are lower in patients with AICU. HLA class II alleles and CU were further investigated in a variety of ethnic groups. Significantly higher frequencies of HLA-DQ1 (Turkey),76 -DQB1*0302 (UK),81 -DRB1*01 (Turkey),79 -DRB1*04 (UK, Turkey and Poland),77,81,82 -DRB1*0901 (China),83 -DRB1*12 (China),83 and -DRB1*15 (Turkey)79 were noted in CU patients. However, HLA-DRB1*15 (UK),81 -DQB1*06 (UK),81 and -DQB1*05 (China)83 were found to be protective factors in CU patients. When HLA class I and II alleles were evaluated in Korean patients with AIU using a high-resolution technique, the frequency of the HLA-DRB1*1302-DQB1*0609-DPB1*0201 haplotype was significantly higher in the patient group.84 Although studies using a high-resolution technique in a larger CU cohort, followed by in vitro functional studies, are essential, these findings suggest the potential involvement of HLA alleles in CU phenotypes.
Two HLA class II alleles, HLA-DQB1*0609 and -DRB1*1302, showed significant associations with the prevalence of serum specific IgE antibodies to staphylococcal enterotoxins A (SEA) and B (SEB) in AICU patients,85 suggesting that patients carrying these HLA alleles may be more susceptible to a Th2 immune response induced by staphylococcal superantigens, which may contribute to the development of AICU.

Other potential genetic mechanisms

Variation in genes encoding acetyl salicylic acid-metabolizing enzymes may affect drug responses and the risk of developing drug intolerance. In humans, aspirin is rapidly deacetylated to salicylic acid. The major enzymes involved in acetylsalicylic acid metabolism are polymorphic enzymes responsible for hydroxylation and glucuronidation of the drug, and include uridine diphosphate (UDP)-glucuronosyltransferase UGT1A6, cytochrome P450 CYP2C9, and N-acetyltransferase 2 (NAT2). Two common variant alleles of UGT1A6, with amino acid changes at positions 181 (T181A) and 184 (R184S), result in an enzyme activity that is reduced to 30%-50% of the wild-type allele.86 In addition, two variants of CYP2C9 alleles, CYP2C9*2 (R144C) and CYP2C9*3 (I359L), yield slow metabolizing enzymes with 5-30% of the activity of the wild-type.87 Due to differences in metabolic efficacy between wild-type and variant phenotypes, it is tempting to reason that carriers of these variants differ in their metabolism in a way that influences aspirin hypersensitivity and CU. Evaluation of genetic polymorphisms with major metabolizing activity, including CYP2C9 -1188T>C, CYP2C9*3 A1075C, UGT1A6 T181A A>G, UGT1A6 R184S A>C, NAT2 -9796T>A, NAT2 197G>A, NAT2 286A>G, NAT2 -9601A>G, and NAT2 -9306A>G, in Korean patients with AIU88 suggests that the CYP2C9 -1188T>C variant may contribute to AIU development by modulating the metabolizing activity of its encoded enzyme.
Angiotensin-converting enzyme (ACE) is widely expressed in the skin and is a major proteolytic peptidase that degrades substance P.89 Substance P is a well-known neuropeptide with the capacity to provoke the release of histamine from skin mast cells. Intradermal injection of substance P induces wheal and flare reactions in normal human skin.90, 91 Genetic variation in the ACE gene has been studied in patients with angioedema and CU patients with angioedema.92-94 Insertion/deletion polymorphisms of the ACE gene showed statistically significant associations with angioedema in CU in a Turkish cohort.94 Although this was a single report with no follow-up studies, the findings suggest that this polymorphism contributes to susceptibility to angioedema in CU patients.
Autoimmune mechanisms are known to be involved in the pathogenesis of CU. One candidate autoimmune mechanism is protein tyrosine phosphatase 22 (PTPN22), which is considered to be an inhibitor of the immunological responses of both T and B cells.95 PTPN22 is expressed by B cells, T cells, and dendritic cells, and is present mainly in the cytoplasm, as well as in the nucleus.95 Genetic variation in this gene has been reported in various autoimmune disorders, including rheumatoid arthritis, type I diabetes, and systemic lupus erythematosus.96-98 Functional variants of this gene may decrease the ability of PTPN22 to reduce antigen-receptor signaling, leading to compromised central and peripheral tolerance.95 PTPN22 was reported to contribute to CU susceptibility in a Polish population.99 The prevalences of the PTPN22 promoter polymorphism -1123G>C, and its haplotype construct including rs2488457C, rs1310182T and 3811021T, showed significant associations with CU. However, the PTPN22 polymorphism 1858C>T did not show an association with CU in autologous serum skin test-positive patients.100 Further association studies of other autoimmune markers in a variety of CU cohorts are needed.

CONCLUSIONS

We summarized the molecular genetic mechanisms underlying CU phenotypes. Because CU is a heterogeneous disease, the phenotype is at present not well-defined and related clinical parameters have not been fully evaluated in each study. Further investigations using GWASs and candidate gene approaches with applying immunologic evaluations should follow. This will improve understanding of the molecular genetic mechanisms underlying CU, facilitate the development of marker genes for differentiation of the various CU phenotypes, and identify potential therapeutic targets.

Figures and Tables

Table 1
Comparison of the clinical characteristics of patients with chronic urticaria according to aspirin hypersensitivity.
aair-6-13-i001
AICU (n=141) ATCU (n=153) P value
Sex (male, %) 48.9 47.7 0.907
Age (years) 35.44±11.54 39.39±11.71 0.004
Atopy (%) 72.1 49.3 <0.001
Log serum total IgE (IU/mL) 5.20±1.05 4.69±1.11 <0.001

Age and serum total IgE: Prsented as mean±SD

AICU, aspirin-intolerant chronic urticaria; ATCU, aspirin-tolerant chronic urticaria

Table 2
Genetic markers significantly associated with chronic urticaria phenotypes.
aair-6-13-i002
Gene RefSNP ID Variation Clinical phenotype Country
Histamine- and mast cell-related genes
FcεRIα rs2427827 -344C>T AICU Korea33
FceRIβ rs569108 E237G AICU Korea34
FceRIγ rs11587213 -237A>G AICU Korea34
HNMT rs1050891 939A>G AICU Korea37
TNF-α rs1799964 Ht: -1031T>C AIU Korea42
rs1800630   -863C>A
rs1799724   -857C>T
rs1800629   -308G>A
rs361525   -238G>A
TGFβ1 rs1800469 -509C>T CU, AICU Iran47
ADORA3 rs10776727 -1050G>T AIU Korea48
IL-10 rs1544224 -564C>T Korea54
rs1800871 -819T>C AIU Korea62
Arachidonic acid pathway related genes
ALOX5 rs4986832 -1708G>A AIU Korea70
rs2228064 270G>A
rs2229136 1728A>G
CysLTR1 rs321029 -634C>T AICU Korea71
LTC4S rs730012 -444A>C AIU Poland74
Venezuela73
PTGER4 rs45613037 -1254A>G AICU Korea20
Other potential mechanisms
CYP2C9 rs4918758 -1188T>C AIU Korea88
ACE rs1799752 Insertion/deletion CU with angioedema Turkey94
PTPN22 rs2488457 Ht: -1123G/C CU Poland99
rs1310182   rs1310182C/T
rs3811021   rs3811021C/T

Both allelic and haplotype associations are shown.

Table 3
Genetic markers of HLA class I and II regions associated with chronic urticaria phenotypes.
aair-6-13-i003
HLA class I HLA class II
Risk Ethnic group Protective Ethnic group Risk Ethnic group Protective Ethnic group
Chronic urticaria Bw4 Turkey76 A24 Turkey76 DRB1*01 Turkey79 DRB1*15 UK81
B14 Brazil78 A33 Poland77 DRB1*04 UK81 DQB1*06 UK81
Turkey82
Poland77
B44 Turkey79 DRB1*0901 China83 DQB1*05 China83
Poland77 DRB1*12 China83
DRB1*15 Turkey79
DQ1 Turkey76
DQB1*0302 UK81
ASA-intolerant chronic urticaria B44 Italy80 A11 Italy80 Ht: DRB1*1302 Korea84
Cw5 Italy80 B13 Italy80  DQB1*0609
Cw4 Italy80  DPB1*0201
Cw7 Italy80

Both allelic and haplotype associations are shown.

ACKNOWLEDGMENTS

This study was supported by a grant from the Korean Health 21 R&D Project, the Ministry of Health & Welfare, Republic of Korea (A111218-11-PG01).

Notes

There are no financial or other issues that might lead to conflict of interest.

References

1. Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J, Canonica GW, Church MK, Godse KV, Grattan CE, Greaves MW, Hide M, Kalogeromitros D, Kaplan AP, Saini SS, Zhu XJ, Zuberbier T. Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report. Allergy. 2011; 66:317–330.
2. Greaves MW. Chronic urticaria. N Engl J Med. 1995; 332:1767–1772.
3. Kaplan AP. Treatment of chronic spontaneous urticaria. Allergy Asthma Immunol Res. 2012; 4:326–331.
4. Asero R. Chronic idiopathic urticaria: a family study. Ann Allergy Asthma Immunol. 2002; 89:195–196.
5. Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau A, Grattan CE, Kapp A, Merk HF, Rogala B, Saini S, Sánchez-Borges M, Schmid-Grendelmeier P, Schünemann H, Staubach P, Vena GA, Wedi B, Maurer M. Global Allergy and Asthma European Network. European Dermatology Forum. World Allergy Organization. EAACI/ GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy. 2009; 64:1417–1426.
6. Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol. 2004; 114:465–474.
7. Confino-Cohen R, Chodick G, Shalev V, Leshno M, Kimhi O, Goldberg A. Chronic urticaria and autoimmunity: associations found in a large population study. J Allergy Clin Immunol. 2012; 129:1307–1313.
8. Najib U, Bajwa ZH, Ostro MG, Sheikh J. A retrospective review of clinical presentation, thyroid autoimmunity, laboratory characteristics, and therapies used in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2009; 103:496–501.
9. Gaig P, Olona M, Muñoz Lejarazu D, Caballero MT, Domínguez FJ, Echechipia S, García Abujeta JL, Gonzalo MA, Lleonart R, Martínez Cócera C, Rodríguez A, Ferrer M. Epidemiology of urticaria in Spain. J Investig Allergol Clin Immunol. 2004; 14:214–220.
10. Staubach P, Dechene M, Metz M, Magerl M, Siebenhaar F, Weller K, Zezula P, Eckhardt-Henn A, Maurer M. High prevalence of mental disorders and emotional distress in patients with chronic spontaneous urticaria. Acta Derm Venereol. 2011; 91:557–561.
11. Chung MC, Symons C, Gilliam J, Kaminski ER. Stress, psychiatric co-morbidity and coping in patients with chronic idiopathic urticaria. Psychol Health. 2010; 25:477–490.
12. Kowalski ML, Makowska JS, Blanca M, Bavbek S, Bochenek G, Bousquet J, Bousquet P, Celik G, Demoly P, Gomes ER, Niżankowska-Mogilnicka E, Romano A, Sanchez-Borges M, Sanz M, Torres MJ, De Weck A, Szczeklik A, Brockow K. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*. Allergy. 2011; 66:818–829.
13. Zuberbier T, Chantraine-Hess S, Hartmann K, Czarnetzki BM. Pseudoallergen-free diet in the treatment of chronic urticaria. A prospective study. Acta Derm Venereol. 1995; 75:484–487.
14. Doña I, Blanca-López N, Cornejo-García JA, Torres MJ, Laguna JJ, Fernández J, Rosado A, Rondón C, Campo P, Agúndez JA, Blanca M, Canto G. Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response. Clin Exp Allergy. 2011; 41:86–95.
15. Gómez E, Torres MJ, Mayorga C, Blanca M. Immunologic evaluation of drug allergy. Allergy Asthma Immunol Res. 2012; 4:251–263.
16. Sánchez-Borges M. NSAID hypersensitivity (respiratory, cutaneous, and generalized anaphylactic symptoms). Med Clin North Am. 2010; 94:853–864.
17. Erbagci Z. Multiple NSAID intolerance in chronic idiopathic urticaria is correlated with delayed, pronounced and prolonged autoreactivity. J Dermatol. 2004; 31:376–382.
18. Kim SH, Park HS. Genetic markers for differentiating aspirin-hypersensitivity. Yonsei Med J. 2006; 47:15–21.
19. Ye YM, Kim JE, Nahm DI, Kim SH, Suh CH, Nahm DH, Park HS. Comparison of clinical characteristics and prognosis of chronic urticaria according to the aspirin sensitivity. Korean J Asthma Allergy Clin Immunol. 2005; 25:194–199.
20. Palikhe NS, Sin HJ, Kim SH, Sin HJ, Hwang EK, Ye YM, Park HS. Genetic variability of prostaglandin E2 receptor subtype EP4 gene in aspirin-intolerant chronic urticaria. J Hum Genet. 2012; 57:494–499.
21. Choi SJ, Ye YM, Hur GY, Shin SY, Han JH, Park HS. Neutrophil activation in patients with ASA-induced urticaria. J Clin Immunol. 2008; 28:244–249.
22. Kim JE, Lee JW, Sung JM, Kim JH, Choi GS, Ye YM, Nahm DH, Park HS. Comparison of clinical characteristics between acute and chronic acetylsalicylic acid-intolerant urticaria. Korean J Asthma Allergy Clin Immunol. 2010; 30:93–99.
23. Luquin E, Kaplan AP, Ferrer M. Increased responsiveness of basophils of patients with chronic urticaria to sera but hypo-respon siveness to other stimuli. Clin Exp Allergy. 2005; 35:456–460.
24. Nam YH, Kim JH, Jin HJ, Hwang EK, Shin YS, Ye YM, Park HS. Effects of omalizumab treatment in patients with refractory chronic urticaria. Allergy Asthma Immunol Res. 2012; 4:357–361.
25. Hide M, Francis DM, Grattan CE, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med. 1993; 328:1599–1604.
26. Niimi N, Francis DM, Kermani F, O'Donnell BF, Hide M, Kobza-Black A, Winkelmann RK, Greaves MW, Barr RM. Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. J Invest Dermatol. 1996; 106:1001–1006.
27. Maurer M, Altrichter S, Bieber T, Biedermann T, Bräutigam M, Seyfried S, Brehler R, Grabbe J, Hunzelmann N, Jakob T, Jung A, Kleine-Tebbe J, Mempel M, Meurer M, Reich K, Ruëff F, Schäkel K, Sengupta K, Sieder C, Simon JC, Wedi B, Zuberbier T, Mahler V, Staubach P. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol. 2011; 128:202–209.e5.
28. Kim MA, Park HS. Highly cytokinergic IgE antibodies and autoimmune mechanisms. Allergy Asthma Immunol Res. 2012; 4:311–312.
29. Ferrer M, Luquin E, Sanchez-Ibarrola A, Moreno C, Sanz ML, Kaplan AP. Secretion of cytokines, histamine and leukotrienes in chronic urticaria. Int Arch Allergy Immunol. 2002; 129:254–260.
30. Hennino A, Bérard F, Guillot I, Saad N, Rozières A, Nicolas JF. Pathophysiology of urticaria. Clin Rev Allergy Immunol. 2006; 30:3–11.
31. Kraft S, Rana S, Jouvin MH, Kinet JP. The role of the FcepsilonRI beta-chain in allergic diseases. Int Arch Allergy Immunol. 2004; 135:62–72.
32. Kraft S, Kinet JP. New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol. 2007; 7:365–378.
33. Bae JS, Kim SH, Ye YM, Yoon HJ, Suh CH, Nahm DH, Park HS. Significant association of FcepsilonRIalpha promoter polymorphisms with aspirin-intolerant chronic urticaria. J Allergy Clin Immunol. 2007; 119:449–456.
34. Palikhe N, Kim SH, Yang EM, Kang YM, Ye YM, Hur GY, Park HS. Analysis of high-affinity IgE receptor (FcepsilonR1) polymorphisms in patients with aspirin-intolerant chronic urticaria. Allergy Asthma Proc. 2008; 29:250–257.
35. Yamauchi K, Sekizawa K, Suzuki H, Nakazawa H, Ohkawara Y, Katayose D, Ohtsu H, Tamura G, Shibahara S, Takemura M, Maeyama K, Watanabe T, Sasaki H, Shirato K, Takishima T. Structure and function of human histamine N-methyltransferase: critical enzyme in histamine metabolism in airway. Am J Physiol. 1994; 267:L342–L349.
36. Fukui K, Miyake Y. Molecular cloning and chromosomal localization of a human gene encoding D-amino-acid oxidase. J Biol Chem. 1992; 267:18631–18638.
37. Kim SH, Kang YM, Kim SH, Cho BY, Ye YM, Hur GY, Park HS. Histamine N-methyltransferase 939A>G polymorphism affects mRNA stability in patients with acetylsalicylic acid-intolerant chronic urticaria. Allergy. 2009; 64:213–221.
38. Choi JH, Kim SH, Suh CH, Nahm DH, Park HS. Polymorphisms of high-affinity IgE receptor and histamine-related genes in patients with ASA-induced urticaria/angioedema. J Korean Med Sci. 2005; 20:367–372.
39. Piconi S, Trabattoni D, Iemoli E, Fusi ML, Villa ML, Milazzo F, Clerici M. Immune profiles of patients with chronic idiopathic urticaria. Int Arch Allergy Immunol. 2002; 128:59–66.
40. Walsh LJ, Trinchieri G, Waldorf HA, Whitaker D, Murphy GF. Human dermal mast cells contain and release tumor necrosis factor alpha, which induces endothelial leukocyte adhesion molecule 1. Proc Natl Acad Sci U S A. 1991; 88:4220–4224.
41. Carroll MC, Katzman P, Alicot EM, Koller BH, Geraghty DE, Orr HT, Strominger JL, Spies T. Linkage map of the human major histocompatibility complex including the tumor necrosis factor genes. Proc Natl Acad Sci U S A. 1987; 84:8535–8539.
42. Choi JH, Kim SH, Cho BY, Lee SK, Kim SH, Suh CH, Park HS. Association of TNF-alpha promoter polymorphisms with aspirin-induced urticaria. J Clin Pharm Ther. 2009; 34:231–238.
43. Higuchi T, Seki N, Kamizono S, Yamada A, Kimura A, Kato H, Itoh K. Polymorphism of the 5'-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens. 1998; 51:605–612.
44. Redington AE, Roche WR, Holgate ST, Howarth PH. Co-localization of immunoreactive transforming growth factor-beta 1 and decorin in bronchial biopsies from asthmatic and normal subjects. J Pathol. 1998; 186:410–415.
45. Gomez G, Ramirez CD, Rivera J, Patel M, Norozian F, Wright HV, Kashyap MV, Barnstein BO, Fischer-Stenger K, Schwartz LB, Kepley CL, Ryan JJ. TGF-beta 1 inhibits mast cell Fc epsilon RI expression. J Immunol. 2005; 174:5987–5993.
46. Bissonnette EY, Enciso JA, Befus AD. TGF-beta1 inhibits the release of histamine and tumor necrosis factor-alpha from mast cells through an autocrine pathway. Am J Respir Cell Mol Biol. 1997; 16:275–282.
47. Hosseini Farahabadi S, Tavakkol-Afshari J, Ganjali R, Rafatpanah H, Ghaffari J, Farid-Hosseini R. Association between the polymorphism of TGF-beta1 gene promoter (-509C>T) and idiopathic chronic urticaria. Iran J Allergy Asthma Immunol. 2006; 5:109–113.
48. Park HJ, Ye YM, Hur GY, Kim SH, Park HS. Association between a TGFbeta1 promoter polymorphism and the phenotype of aspirin-intolerant chronic urticaria in a Korean population. J Clin Pharm Ther. 2008; 33:691–697.
49. Kim SH, Park HS, Holloway JW, Shin HD, Park CS. Association between a TGFbeta1 promoter polymorphism and rhinosinusitis in aspirin-intolerant asthmatic patients. Respir Med. 2007; 101:490–495.
50. Silverman ES, Palmer LJ, Subramaniam V, Hallock A, Mathew S, Vallone J, Faffe DS, Shikanai T, Raby BA, Weiss ST, Shore SA. Transforming growth factor-beta1 promoter polymorphism C-509T is associated with asthma. Am J Respir Crit Care Med. 2004; 169:214–219.
51. Marquardt DL, Gruber HE, Wasserman SI. Adenosine release from stimulated mast cells. Proc Natl Acad Sci U S A. 1984; 81:6192–6196.
52. Ramkumar V, Stiles GL, Beaven MA, Ali H. The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J Biol Chem. 1993; 268:16887–16890.
53. Reeves JJ, Jones CA, Sheehan MJ, Vardey CJ, Whelan CJ. Adenosine A3 receptors promote degranulation of rat mast cells both in vitro and in vivo. Inflamm Res. 1997; 46:180–184.
54. Kim SH, Nam EJ, Kim YK, Ye YM, Park HS. Functional variability of the adenosine A3 receptor (ADORA3) gene polymorphism in aspirin-induced urticaria. Br J Dermatol. 2010; 163:977–985.
55. Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2011; 29:71–109.
56. O'Garra A, Vieira P. T(H)1 cells control themselves by producing interleukin-10. Nat Rev Immunol. 2007; 7:425–428.
57. Maynard CL, Weaver CT. Diversity in the contribution of interleukin-10 to T-cell-mediated immune regulation. Immunol Rev. 2008; 226:219–233.
58. Salim PH, Jobim M, Bredemeier M, Chies JA, Brenol JC, Jobim LF, Xavier RM. Interleukin-10 gene promoter and NFKB1 promoter insertion/deletion polymorphisms in systemic sclerosis. Scand J Immunol. 2013; 77:162–168.
59. Salhi A, Rodrigues V Jr, Santoro F, Dessein H, Romano A, Castellano LR, Sertorio M, Rafati S, Chevillard C, Prata A, Alcaïs A, Argiro L, Dessein A. Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis. J Immunol. 2008; 180:6139–6148.
60. Ates O, Müsellim B, Ongen G, Topal-Sarikaya A. Association between 'interleukin' 10 gene (IL10) polymorphisms and systemic sclerosis with interstitial lung involvement. Rheumatol Int. 2008; 28:1123–1126.
61. Beretta L, Cappiello F, Barili M, Scorza R. Proximal interleukin-10 gene polymorphisms in Italian patients with systemic sclerosis. Tissue Antigens. 2007; 69:305–312.
62. Palikhe NS, Kim SH, Jin HJ, Nam YH, Park HS. Association of interleukin 10 promoter polymorphism at -819 T>C with aspirin-induced urticaria in a Korean population. Ann Allergy Asthma Immunol. 2011; 107:544–546.
63. Kennedy Norton S, Barnstein B, Brenzovich J, Bailey DP, Kashyap M, Speiran K, Ford J, Conrad D, Watowich S, Moralle MR, Kepley CL, Murray PJ, Ryan JJ. IL-10 suppresses mast cell IgE receptor expression and signaling in vitro and in vivo. J Immunol. 2008; 180:2848–2854.
64. Grimbaldeston MA, Nakae S, Kalesnikoff J, Tsai M, Galli SJ. Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat Immunol. 2007; 8:1095–1104.
65. Setkowicz M, Mastalerz L, Podolec-Rubis M, Sanak M, Szczeklik A. Clinical course and urinary eicosanoids in patients with aspirin-induced urticaria followed up for 4 years. J Allergy Clin Immunol. 2009; 123:174–178.
66. Narayanankutty A, Reséndiz-Hernández JM, Falfán-Valencia R, Teran LM. Biochemical pathogenesis of aspirin exacerbated respiratory disease (AERD). Clin Biochem. 2013; 46:566–578.
67. Celik G, Bavbek S, Misirligil Z, Melli M. Release of cysteinyl leukotrienes with aspirin stimulation and the effect of prostaglandin E(2) on this release from peripheral blood leucocytes in aspirin-induced asthmatic patients. Clin Exp Allergy. 2001; 31:1615–1622.
68. Feng C, Beller EM, Bagga S, Boyce JA. Human mast cells express multiple EP receptors for prostaglandin E2 that differentially modulate activation responses. Blood. 2006; 107:3243–3250.
69. Cornejo-García JA, Jagemann LR, Blanca-López N, Doña I, Flores C, Guéant-Rodríguez RM, Torres MJ, Fernández J, Laguna JJ, Rosado A, Agúndez JA, García-Martín E, Canto G, Guéant JL, Blanca M. Genetic variants of the arachidonic acid pathway in non-steroidal anti-inflammatory drug-induced acute urticaria. Clin Exp Allergy. 2012; 42:1772–1781.
70. Kim SH, Choi JH, Holloway JW, Suh CH, Nahm DH, Ha EH, Park CS, Park HS. Leukotriene-related gene polymorphisms in patients with aspirin-intolerant urticaria and aspirin-intolerant asthma: differing contributions of ALOX5 polymorphism in Korean population. J Korean Med Sci. 2005; 20:926–931.
71. Kim SH, Yang EM, Park HJ, Ye YM, Lee HY, Park HS. Differential contribution of the CysLTR1 gene in patients with aspirin hypersensitivity. J Clin Immunol. 2007; 27:613–619.
72. Mastalerz L, Setkowicz M, Sanak M, Szczeklik A. Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. J Allergy Clin Immunol. 2004; 113:771–775.
73. Sánchez-Borges M, Acevedo N, Vergara C, Jiménez S, Zabner-Oziel P, Monzón A, Caraballo L. The A-444C polymorphism in the leukotriene C4 synthase gene is associated with aspirin-induced urticaria. J Investig Allergol Clin Immunol. 2009; 19:375–382.
74. Mastalerz L, Setkowicz M, Sanak M, Rybarczyk H, Szczeklik A. Familial aggregation of aspirin-induced urticaria and leukotriene C synthase allelic variant. Br J Dermatol. 2006; 154:256–260.
75. Torres-Galván MJ, Ortega N, Sánchez-García F, Blanco C, Carrillo T, Quiralte J. LTC4-synthase A-444C polymorphism: lack of association with NSAID-induced isolated periorbital angioedema in a Spanish population. Ann Allergy Asthma Immunol. 2001; 87:506–510.
76. Aydogan K, Karadogan SK, Akdag I, Tunali S. HLA class I and class II antigens in Turkish patients with chronic ordinary urticaria. Clin Exp Dermatol. 2006; 31:424–429.
77. Bozek A, Krajewska J, Filipowska B, Polanska J, Rachowska R, Grzanka A, Jarzab J. HLA status in patients with chronic spontaneous urticaria. Int Arch Allergy Immunol. 2010; 153:419–423.
78. Calamita Z, Bronhara Pelá Calamita A. HLA in patients with chronic spontaneous urticaria who are positive for anti-thyroid antibodies. J Eur Acad Dermatol Venereol. 2013; 27:661–662.
79. Coban M, Erdem T, Ozdemir S, Pirim I, Atasoy M, Ikbal M. HLA class I and class II genotyping in patients with chronic urticaria. Int Arch Allergy Immunol. 2008; 147:135–139.
80. Pacor ML, Di Lorenzo G, Mansueto P, Martinelli N, Esposito-Pellitteri M, Pradella P, Uxa L, Di Fede G, Rini G, Corrocher R. Relationship between human leucocyte antigen class I and class II and chronic idiopathic urticaria associated with aspirin and/or NSAIDs hypersensitivity. Mediators Inflamm. 2006; 2006:62489.
81. O'Donnell BF, O'Neill CM, Francis DM, Niimi N, Barr RM, Barlow RJ, Kobza Black A, Welsh KI, Greaves MW. Human leucocyte antigen class II associations in chronic idiopathic urticaria. Br J Dermatol. 1999; 140:853–858.
82. Oztas P, Onder M, Gonen S, Oztas MO, Soylemezoglu O. Is there any relationship between human leucocyte antigen class II and chronic urticaria? (chronic urticaria and HLA class II). Yonsei Med J. 2004; 45:392–395.
83. Chen J, Tan Z, Li J, Xiong P. Association of HLA-DRB1, DQB1 alleles with chronic urticaria. J Huazhong Univ Sci Technolog Med Sci. 2005; 25:354–356.
84. Kim SH, Choi JH, Lee KW, Kim SH, Shin ES, Oh HB, Suh CH, Nahm DH, Park HS. The human leucocyte antigen-DRB1*1302-DQB1*0609-DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria. Clin Exp Allergy. 2005; 35:339–344.
85. Ye YM, Hur GY, Park HJ, Kim SH, Kim HM, Park HS. Association of specific IgE to staphylococcal superantigens with the phenotype of chronic urticaria. J Korean Med Sci. 2008; 23:845–851.
86. Ciotti M, Marrone A, Potter C, Owens IS. Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications. Pharmacogenetics. 1997; 7:485–495.
87. Bigler J, Whitton J, Lampe JW, Fosdick L, Bostick RM, Potter JD. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res. 2001; 61:3566–3569.
88. Palikhe NS, Kim SH, Nam YH, Ye YM, Park HS. Polymorphisms of aspirin-metabolizing enzymes CYP2C9, NAT2 and UGT1A6 in aspirin-intolerant urticaria. Allergy Asthma Immunol Res. 2011; 3:273–276.
89. Petrov V, Fagard R, Lijnen P. Effect of protease inhibitors on angiotensin-converting enzyme activity in human T-lymphocytes. Am J Hypertens. 2000; 13:535–539.
90. Foreman JC, Jordan CC, Oehme P, Renner H. Structure-activity relationships for some substance P-related peptides that cause wheal and flare reactions in human skin. J Physiol. 1983; 335:449–465.
91. Piotrowski W, Foreman JC. On the actions of substance P, somatostatin, and vasoactive intestinal polypeptide on rat peritoneal mast cells and in human skin. Naunyn Schmiedebergs Arch Pharmacol. 1985; 331:364–368.
92. Bas M, Hoffmann TK, Tiemann B, Dao VT, Bantis C, Balz V, Schultz-Coulon HJ, Stark T, Schuler P, Greve J, Ivens K, Bier H, Kojda G. Potential genetic risk factors in angiotensin-converting enzyme-inhibitor-induced angio-oedema. Br J Clin Pharmacol. 2010; 69:179–186.
93. Gulec M, Caliskaner Z, Tunca Y, Ozturk S, Bozoglu E, Gul D, Erel F, Kartal O, Karaayvaz M. The role of ace gene polymorphism in the development of angioedema secondary to angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Allergol Immunopathol (Madr). 2008; 36:134–140.
94. Akcali C, Ozkur M, Erbagci Z, Benlier N, Aynacioglu AS. Association of insertion/deletion polymorphism of the angiotensin-converting enzyme gene with angio-oedema accompanying chronic urticaria but not chronic urticaria without angio-oedema or the autologous serum skin test response. J Eur Acad Dermatol Venereol. 2008; 22:83–86.
95. Rhee I, Veillette A. Protein tyrosine phosphatases in lymphocyte activation and autoimmunity. Nat Immunol. 2012; 13:439–447.
96. Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC, Ardlie KG, Huang Q, Smith AM, Spoerke JM, Conn MT, Chang M, Chang SY, Saiki RK, Catanese JJ, Leong DU, Garcia VE, McAllister LB, Jeffery DA, Lee AT, Batliwalla F, Remmers E, Criswell LA, Seldin MF, Kastner DL, Amos CI, Sninsky JJ, Gregersen PK. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet. 2004; 75:330–337.
97. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M, MacMurray J, Meloni GF, Lucarelli P, Pellecchia M, Eisenbarth GS, Comings D, Mustelin T. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet. 2004; 36:337–338.
98. Kyogoku C, Langefeld CD, Ortmann WA, Lee A, Selby S, Carlton VE, Chang M, Ramos P, Baechler EC, Batliwalla FM, Novitzke J, Williams AH, Gillett C, Rodine P, Graham RR, Ardlie KG, Gaffney PM, Moser KL, Petri M, Begovich AB, Gregersen PK, Behrens TW. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet. 2004; 75:504–507.
99. Brzoza Z, Grzeszczak W, Rogala B, Trautsolt W, Moczulski D. PTPN22 polymorphism presumably plays a role in the genetic background of chronic spontaneous autoreactive urticaria. Dermatology. 2012; 224:340–345.
100. Brzoza Z, Grzeszczak W, Trautsolt W, Moczulski D. Protein tyrosine phosphatase-22 (PTPN-22) polymorphism in the pathogenesis of chronic urticaria. Allergy. 2011; 66:1392–1393.
TOOLS
ORCID iDs

Hae-Sim Park
https://orcid.org/http://orcid.org/0000-0003-2614-0303

Similar articles